NuVasive reports Q2 non-GAAP EPS 56c, consensus 55c

Reports Q2 revenue $317.8greater thanM, consensus $322.05M. “I’d like to congratulate our team on another solid quarter,” said Chris Barry, CEO. “Our results reflect the strength of our differentiated product portfolios and continued commercial execution. Looking ahead, we remain excited and committed to combining with Globus Medical. And in doing so, drive value creation for our shareholders as we help change more patient lives around the globe.”